<DOC>
	<DOCNO>NCT02063698</DOCNO>
	<brief_summary>This randomize pilot clinical trial study whether auranofin relieve pain follow paclitaxel patient previously experience paclitaxel-induced pain . Auranofin drug give mouth treat disease rheumatoid arthritis , study see decrease pain follow paclitaxel .</brief_summary>
	<brief_title>Auranofin Decreasing Pain Patients With Paclitaxel-Induced Pain Syndrome</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine whether one dose auranofin give day follow administration paclitaxel decrease pain assessed daily completion Modified Brief Pain Inventory scale seven day . SECONDARY OBJECTIVES : I. Assess whether auranofin well tolerated setting . OUTLINE : Patients randomize 1 2 treatment arm . ARM I : Patients receive auranofin orally ( PO ) day 2 . ARM II : Patients receive placebo PO day 2 . After completion study treatment , patient follow 21-28 day .</detailed_description>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Auranofin</mesh_term>
	<criteria>Absolute neutrophil count ( ANC ) &gt; = 1500/mm^3 Platelet count ( PLT ) &gt; = 100,000/mm^3 Creatinine = &lt; 2 x upper limit normal ( ULN ) Either serum glutamate pyruvate transaminase ( SGPT ) ( alanine aminotransferase [ ALT ] ) serum glutamic oxaloacetic transaminase ( SGOT ) ( aspartate aminotransferase [ AST ] ) = &lt; 1.5 x ULN Total/direct bilirubin = &lt; 1.5 x ULN Alkaline phosphatase = &lt; 1.5 x ULN Hemoglobin &gt; = 9 mg/dL Negative urine serum pregnancy test perform = &lt; 7 day prior registration , woman childbearing potential Previously experience paclitaxel induce pain current past paclitaxel treatment treat healthcare provider think consistent paclitaxelinduced acute pain syndrome ; note : formal documentation prior pain require Scheduled receive paclitaxel dose &gt; = 70 mg/m^2 = &lt; 14 day randomization Ability complete questionnaire assistance Pregnant woman Nursing woman Any woman childbearing potential male partner woman childbearing potential unwilling employ acceptable contraception throughout study least 30 day last dose study drug History goldinduced disorder , include limited , necrotizing enterocolitis , pulmonary fibrosis , exfoliative dermatitis , bone marrow aplasia severe hematologic disorder ; history severe allergic anaphylactic reaction hypersensitivity auranofin gold compound Currently receive Dilantin ( phenytoin ) auranofin another goldcontaining compound Anticipated use filgrastim ( GCSF ) sargramostim ( GMCSF ) within 30 day receive auranofin Currently receive immunemodulating therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>